News | November 07, 2024
RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Strokes are affecting approximately 1.8 million people annually
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Quinidine Sulphate helps manage rare irregular heartbeat conditions
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
The emergence of new infections in India is a growing concern
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
Subscribe To Our Newsletter & Stay Updated
